Literature DB >> 2353184

Bubble and membrane oxygenators--comparison of postoperative organ dysfunction with special reference to inflammatory activity.

L Nilsson1, H Tydén, O Johansson, U Nilsson, G Ronquist, P Venge, T Aberg, S O Nyström.   

Abstract

Bubble and membrane oxygenators (2 types of each) were compared in a randomized study of 96 patients undergoing coronary bypass grafting. Cardiac performance, assessed from postoperative need of inotropic support, was significantly better in the membrane oxygenator group. After perfusion lasting more than 2 hours, respiratory function, measured as alveolar-arterial oxygen pressure gradient, was less compromised in that group and renal function, quantified as postoperative rise of serum creatinine was less disturbed. Cerebral function, studied in terms of psychometric test results and concentration of adenylate kinase in cerebrospinal fluid, did not differ between the bubble and membrane oxygenator groups. In investigations concerning changes in inflammatory activity during bypass, complement activation could not be related to the mentioned clinical parameters. Release of the neutrophil granulocyte factors lactoferrin and myeloperoxidase was greater in the bubble oxygenator group and correlated to impaired cardiac and renal performance, but not to pulmonary or cerebral dysfunction.

Entities:  

Mesh:

Year:  1990        PMID: 2353184     DOI: 10.3109/14017439009101825

Source DB:  PubMed          Journal:  Scand J Thorac Cardiovasc Surg        ISSN: 0036-5580


  2 in total

1.  IL-6 and TNF alpha release in association with neutrophil activation after cardiopulmonary bypass surgery.

Authors:  R G Holzheimer; R G Molloy; H Görlach; S Wilkert; F Hehrlein
Journal:  Infection       Date:  1994 Jan-Feb       Impact factor: 3.553

2.  Effect of Ascorbic Acid on Cardiac Surgery-Associated Acute Kidney Injury Incidence.

Authors:  Anze Djordjevic; Stamenko Susak; Petra Kotnik; Mario Gorenjak; Zeljko Knez; Miha Antonic
Journal:  Thorac Cardiovasc Surg       Date:  2022-05-28       Impact factor: 1.756

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.